FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

スタックライブラリ

Deep Sleep + GH Stack

Sleep Optimizationintermediate

85

シナジー

85
Share
ペプチド

3

平均日用量mcg

5,400

レベル

intermediate

追加

May 17, 2026

概要

The Deep Sleep + GH Stack is a comprehensive nocturnal optimization protocol that combines sleep induction, circadian rhythm restoration, and GH pulse amplification — targeting all three systems that govern what the body accomplishes during sleep. DSIP (Delta Sleep-Inducing Peptide) increases slow-wave sleep duration and quality. Slow-wave sleep is the stage when growth hormone is secreted, cellular repair occurs, and memories are consolidated. DSIP normalizes sleep architecture rather than forcing sedation — it works with the brain''s natural sleep regulation rather than bypassing it. Epithalon, administered in a 10-day course, targets the deeper circadian regulation governed by the pineal gland. As we age, the pineal''s melatonin production and overall regulatory function decline, disrupting the circadian rhythms that govern when the body performs repair, immune surveillance, and hormonal secretion. Epithalon''s activation of telomerase and pineal function restores more youthful circadian patterns — longer, deeper sleep with more consistent timing. CJC-1295 amplifies the GH pulse that naturally occurs during slow-wave sleep. By administering it in the evening before sleep, users time the CJC-1295-driven GH surge to coincide with the DSIP-enhanced slow-wave sleep period. The result is a significantly larger nocturnal GH secretion event — greater than DSIP or CJC-1295 would produce independently. This stack treats sleep as the metabolic and regenerative event it is, rather than just as rest. It is particularly powerful for anti-aging applications, post-injury recovery, and body composition optimization — all domains where nocturnal GH secretion is a primary driver of outcomes.

投与プロトコル

DSIP

nightly· subcutaneous

DSIPについて詳しく読む →

100 mcg

1回の投与あたり

Epithalon

nightly (10-day course)· subcutaneous

Epithalonについて詳しく読む →

5,000 mcg

1回の投与あたり

CJC-1295

nightly· subcutaneous

CJC-1295について詳しく読む →

300 mcg

1回の投与あたり

目標と証拠

Deep sleep qualityGH optimizationAnti-agingCircadian rhythm restorationRecovery
証拠ランク:動物実験

Comments

Sign in to join the discussion

注意: このスタックはコミュニティから提出され、研究用のみです。Peptide Contactsは提出されたスタックの安全性や効果性を確認していません。使用するペプチドプロトコル前に常に資格のある医療専門家に相談してください。